Case report: incessant ventricular fibrillation in a conscious left ventricular assist device patient

Aiste Monika Jakstaite, Peter Luedike, Reza Wakili, Simon Kochhäuser, Arjang Ruhparwar, Tienush Rassaf, and Maria Papathanasiou

1Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany; and 2Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany

Received 16 March 2021; first decision 10 May 2021; accepted 5 August 2021; online publish-ahead-of-print 7 September 2021

Background
Ventricular arrhythmia in left ventricular assist device (LVAD) recipients represents a challenging clinical scenario and the optimal treatment strategy in this unique patient population still needs to be defined.

Case summary
We report on a 61-year-old LVAD patient with incessant ventricular fibrillation (VF) despite multiple unsuccessful attempts to restore normal rhythm with external defibrillation and antiarrhythmic medication. He remained initially stable as an outpatient and subsequently developed secondary organ failure.

Discussion
This case demonstrates that under LVAD support long-term haemodynamic stability is possible even in case of VF, a situation that resembles Fontan circulation. However, ventricular arrhythmias are associated with a high risk of secondary organ damage due to right heart failure if left untreated. In case of refractory ventricular tachycardia or electrical storm listing for heart transplantation with high priority status should be pursued when possible. Alternatively, catheter ablation may be considered in selected cases and be performed in experienced centres in close collaboration with all involved specialists.

Keywords
Heart failure • Left ventricular assist device • Ventricular arrhythmias • Ventricular fibrillation • Electrical storm • Case report

Introduction
The burden of ventricular arrhythmias in left ventricular assist device (LVAD) patients is known to be high. In this setting, ventricular arrhythmias can be well-tolerated but if persistent, they may lead to haemodynamic compromise, right ventricular (RV) failure, and secondary organ dysfunction. The management of ventricular arrhythmias in LVAD patients remains challenging and requires close monitoring and prompt intervention.
collaboration of heart failure cardiologists, arrhythmologists, and heart transplant surgeons. We report here on a patient under long-term LVAD support who presented with long-lasting ventricular fibrillation (VF).

Timeline

| Day 1 | Admission for progressive dyspnoea NYHA class IV and anasarca, electrocardiogram demonstrates ventricular fibrillation (VF) while patient remains fully conscious, internal cardioverter defibrillator interrogation reveals ongoing VF for >2 months prior to admission. History of type 2 amiodarone-induced thyrotoxicosis diagnosed 4 months prior to current admission with subsequent discontinuation of amiodarone and initiation of thiamazole therapy with now normal thyroid function tests. |
| Day 21 | Trans-oesophageal echocardiogram without evidence of intracardiac thrombi, three unsuccessful external defibrillations, re-initiation of oral amiodarone 800 mg/day as a bail-out option. |
| Day 28 | Three unsuccessful external defibrillations, discontinuation of amiodarone. |
| Day 42 | Acute kidney injury with anuria, admission to the intensive care unit, and initiation of continuous veno-venous haemodialysis. |
| Day 43 | Exacerbation of chronic driveline infection firstly diagnosed 10 months ago (6 years of post-left ventricular assist device implantation), further clinical deterioration, shared decision for best supportive care. |
| Day 46 | Death due to septic shock with multi-organ failure. |

Case presentation

A 61-year-old male patient with advanced heart failure under LVAD support presented to the emergency department with worsening dyspnoea, NYHA Class IV, and massive lower extremity and scrotal oedema. A continuous-flow LVAD had been implanted 7 years ago due to dilated cardiomyopathy with heart failure refractory to medical therapy. During LVAD support, the patient developed morbid obesity (body mass index 41 kg/m²) and chronic driveline infection. At presentation, arterial pulse was absent with normal capillary refill time. The core temperature was normal. The neurologic exam was unremarkable. Electrocardiogram demonstrated VF (Figure 1). Interrogation of the implanted cardioverter defibrillator revealed VF while antitachycardic therapy had been previously deactivated due to RV lead malfunction. Left ventricular assist device interrogation showed no acute deviations of pump flow and power readings from the patient’s baseline (pump flow 6.0 L/min, power 5.0 W). Laboratory testing showed elevated serum creatinine (2.3 mg/dL, reference, 0.9–1.3 mg/dL) and N-terminal prohormone of brain natriuretic peptide (39 330 pg/mL, reference, <125 pg/mL). Serum lactate level in venous blood was 3.5 mmol/L (reference, 0.5–1.6 mmol/L). Trans-oesophageal echocardiography was then performed that depicted global akinesia of all cardiac chambers with profound dilation of the right ventricle and faint movements of the tricuspid valve leaflets, a situation resembling Fontan circulation (Figure 2 and Videos 1 and 2). We initiated intravenously furosemide to relieve congestion and performed external defibrillation after excluding intracardiac thrombosis with trans-oesophageal echocardiography. After multiple unsuccessful attempts to restore normal rhythm with external defibrillation, oral amiodarone was initiated followed again by multiple unsuccessful defibrillations. Due to morbid obesity despite multiple dietary consultations and the patient’s wish not to proceed to bariatric surgery due to the high procedural risk, listing for heart transplantation was not possible. It was a shared decision to refrain from performing catheter ablation in the setting of severe comorbidities including morbid obesity, severe renal failure, chronic driveline infection, and incessant VF. The patient eventually developed end-stage renal failure and died due to complications of sepsis.

Discussion

The burden of ventricular arrhythmias in LVAD recipients is known to be high and VF has been reported to affect >10% of patients after LVAD implantation. In the ASSIST-ICD study, 494 LVAD patients, of whom 75% had an internal cardioverter defibrillator (ICD) in place were followed up in 19 tertiary French centres. Late ventricular arrhythmias (>30 days post-implantation) affected 27% of patients after a median follow-up of 19 months and electrical storm occurred in 9% of patients. Ventricular fibrillation or combined VT/VF was observed in 39% of patients with electrical storm. As the number of implants and the duration of support continue to rise it is anticipated that ventricular arrhythmias including VF will further evolve to a challenging clinical problem.

Ventricular arrhythmias under LVAD support are usually well-tolerated but if persistent may lead to collapse of the left ventricle, haemodynamic instability, or RV failure. In order to avoid painful shocks in conscious state and considering the unclear survival benefit with ICD in this population, shock therapy is often deactivated and elective replacement of the generator or any malfunctioning leads may be deferred according to the individual patient needs. This case demonstrates that long-term haemodynamic stability is possible even in the context of VF in LVAD supported circulation and may even remain unrecognized until severe congestion or end-organ dysfunction occur. However, VF is an extreme clinical scenario with atrial and ventricular near-standstill and unpredictable clinical outcome. It may also promote intracardiac thrombosis and embolic events due to blood...
stasis or slow flow. Right ventricular volume and pressure overload may lead to secondary organ failure if left untreated for prolonged period of time. Presumably, normal pulmonary vascular resistance is a prerequisite for maintaining long-term stability in this context and thus, pulmonary hypertension may be a therapeutic target in such patients but should be carefully balanced against potential side effects.7,8

In LVAD, patients with recurrent ventricular tachycardias despite antiarrhythmic therapy catheter ablation should be considered as an alternative treatment option. This strategy requires highly experienced operators, familiarity with the LVAD physiology, and close collaboration between heart failure cardiologists and arrhythmologists.9 Although catheter ablation is often the only alternative in cases of sustained ventricular tachycardia, there are nearly no data in the context of incessant VF, which is completely refractory to defibrillation. Recent studies on catheter-free, non-invasive cardiac radioablation using stereotactic body radiation therapy for ventricular tachycardias have shown promising results that could be of interest for the LVAD population.10 Cardiac sympathetic denervation could also be a promising new therapeutic option for the management of recurrent ventricular arrhythmias.11 Heart transplantation represents the optimal therapy for patients who experience refractory ventricular arrhythmias or VF during LVAD support. In this case, listing with a high
priority status has to be considered timely if no other contraindications exist to avoid secondary organ damage.

Lead author biography

Ms. Aiste Monika Jakstaite is a resident in internal medicine and cardiology at the West German Heart and Vascular Center in Essen, Germany. After graduating from medical school in Vilnius, Lithuania, she moved to Germany and began her doctoral thesis on the role of phosphodiesterase 5 inhibitor in mechanical circulatory support. Her research interest focuses on advanced heart failure and cardiac amyloidosis. Since 2020, she serves as junior editor in EHJ Case Reports.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: none declared.

Video 1 Mid-oesophageal four-chamber view during ventricular fibrillation. Profound dilation of right heart cavities with akinetic tricuspid valve leaflets whereas mitral valve opening and closure is preserved under left ventricular assist device support. LVAD, left ventricular assist device.

Video 2 Mid-oesophageal long-axis view during ventricular fibrillation. Visualization of the left ventricular assist device inflow cannula in the cardiac apex. Dilated right ventricle and decreased internal diameter of the left ventricle under concurrent left ventricular assist device unloading. LVAD, left ventricular assist device.

Funding: This work was supported by the Universitätsmedizin Essen Clinician Scientist Academy (UMEA) and the German Research Foundation (DFG, Deutsche Forschungs-Gemeinschaft) [FU356/12-1 to M.P], and the DFG [LU2139/2-1 to P.L. and RA969/12-1 to T.R.].

Acknowledgements

The authors are indebted to the staff of the advanced Heart Failure Unit for their devotion to the care of LVAD patients.

References

1. Gopinathannair R, Cornwell WK, Dukes JW, Ellis CR, Hickey KT, Joglar JA et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the American Heart Association. Circulation 2019;139:e967–e989.
2. Enriquez AD, Calenda B, Miller MA, Anyanwu AC, Pinney SP. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol 2013;6:668–674.
3. Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C et al. Predictors and clinical impact of late ventricular arrhythmias in patients with continuous-flow left ventricular assist devices. JACC Clin Electrophysiol 2018;4:1166–1175.
4. Martins RP, Leclercq C, Bourenane H, Auffret V, Boulé S, Loobuyck V et al. Incidence, predictors, and clinical impact of electrical storm in patients with left ventricular assist devices: new insights from the ASSIST-ICD study. Heart Rhythm 2019;16:1506–1512.
5. Gopinathannair R, Roukoz H, Bhan A, Ravichandran A, Ahmed MM, Familtsiv D et al. Cardiac resynchronization therapy and clinical outcomes in continuous flow left ventricular assist device recipients. J Am Heart Assoc 2018;7:e009091.
6. Kutyifa V, Fernandez G, Sherazi S, Aikas M, Huang D, McNitt S et al. Implantable cardioverter defibrillators and survival in continuous-flow left ventricular assist device patients. ASAIO J 2019;65:49–53.
7. Xanthopoulos A, Tripopkiadis K, Tripopkiadis F, Fukamachi K, Soltész EG, Young JB et al. Postimplant phosphodiesterase type 5 inhibitors use is associated with lower rates of thrombotic events after left ventricular assist device implantation. J Am Heart Assoc 2020;9:e015897.
8. Papathanasiou M, Ruhparwar A, Kantler M, Rassaf T, Luedike P. Off-label use of pulmonary vasodilators after left ventricular assist device implantation: calling in the evidence. Pharmacol Ther 2020;214:107619.

9. Moss JD, Flatley EE, Besser AD, Shin JH, Nayak HM, Upadhyay GA et al. Characterization of ventricular tachycardia after left ventricular assist device implantation as destination therapy: a single-center ablation experience. JACC Clin Electrophysiol 2017;3:1412–1424.

10. Cuculich PS, Schill MR, Kashani R, Matic S, Lang A, Cooper D et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med 2017;377:2325–2336.

11. Vlismas PP, Rochlani YM, Romero J, Scheinin S, Shin JJ, Goldstein D et al. Cardiac sympathetic denervation for refractory ventricular arrhythmia in continuous-flow left ventricular assist device. J Am Coll Cardiol Case Rep 2021;3:443–446.